Dear partners of GKM, in our opinion, the basis for a good and long-term cooperation is trust and continuity. Since GKM’s foundation in 1981, these values, together with a growing number of motivated employees, enabled us, Siegfried K. Hippe and Renate E. Hippe, to develop the company into an internationally operating CRO.
As the coordinator or manager of a clinical trial, I have one simple goal: I want my clinical trial to be successful. However, to guarantee success, I need to be able to manage my project efficiently. But what system is suitable for this?[...]
The for mid-2017 expected final version of the ICH-GCP guideline addendum takes the subject risk management to the next level: the extent and implementation of a risk-based quality management for a clinical trial no longer remains within the judgement of the sponsor but actually becomes a legal obligation. [...]
GKM’s „Lessons Learned” whitepaper series enters a second round. This time, we focus on psoriasis. We can rely on our experience in this field from 20 years and 21 clinical and non-interventional studies [...]
This year’s EMWA symposium in Munich provided an excellent overview on the diverse and fast-changing world of medical writing. Far from dealing only with dry and difficult matters, as outsiders might suspect, medical writing essentially revolves around all shades of effective communication in the world of medicine [...]
Today we would like to start off “Lessons Learned” with inflammatory bowel diseases, a group of indications which we have accompanied for 25 years. Insights from [...]
We take part in the initiative “My dad reads aloud” - The German Reading Foundation has initiated a program throughout Germany that aims to encourage parents to read out more to their children (e.g. bed time stories). Reading is fundamental to human development, it ignites children’s’ imagination, it opens the view on a different world [...]
Dear reader, clinical research has me now for over 30 years and although this business is often described as one of the slower and less innovative areas, I would strongly argue the opposite! With an innovation share of 9 and 7 % respectively, the pharmaceutical and medical device industry rather show a strong innovative power [...]
